Prices as of 2026/10/30 close
Company comparison · Major Pharmaceuticals
Kyowa Kirin (¥496.8B) and Sumitomo Pharma (¥453.3B) are about the same size by revenue.
Revenue growth in the latest results: Sumitomo Pharma +13.7%, Kyowa Kirin +0.3%.
Kyowa Kirin pays more on average — ¥9.94M against ¥9.06M at Sumitomo Pharma.
Over the past year the shares moved Sumitomo Pharma +13.9%, Kyowa Kirin +7.1%.
Head-to-head wins12 metrics
One win per metric for the company with the best value. Metrics with no better or worse (P/E, average age, employees) are excluded.
ScaleInvestors
EvenKyowa Kirin 1 : Sumitomo Pharma 1
Revenue: Kyowa Kirin ¥496.8B / Sumitomo Pharma ¥453.3B
ProfitabilityInvestors
Sumitomo Pharma aheadKyowa Kirin 0 : Sumitomo Pharma 2
Net margin: Kyowa Kirin 13.5% / Sumitomo Pharma 23.6%
GrowthInvestors
Sumitomo Pharma aheadKyowa Kirin 1 : Sumitomo Pharma 2
Revenue growth (YoY): Kyowa Kirin +0.3% / Sumitomo Pharma +13.7%
Stock & balance sheetInvestors
Sumitomo Pharma aheadKyowa Kirin 0 : Sumitomo Pharma 2
Share price, 1 year: Kyowa Kirin +7.1% / Sumitomo Pharma +13.9%
Pay & workforceJob seekers
Kyowa Kirin aheadKyowa Kirin 2 : Sumitomo Pharma 1
Average salary: Kyowa Kirin ¥9.94M / Sumitomo Pharma ¥9.06M
| Metric | Kyowa Kirin | Sumitomo Pharma | Gap |
|---|---|---|---|
| Revenue | ◎¥496.8B | ¥453.3B | 1.1x |
| Operating profit | — | ¥107.3B | |
| Net income | ¥67.0B | ◎¥106.9B | 1.6x |
| Metric | Kyowa Kirin | Sumitomo Pharma | Gap |
|---|---|---|---|
| Operating margin | — | 23.7% | |
| Net margin | 13.5% | ◎23.6% | 10.1pt |
| ROE | 7.7% | — | |
| Revenue per employee | ¥124M | ◎¥259M | 2.1x |
| Metric | Kyowa Kirin | Sumitomo Pharma | Gap |
|---|---|---|---|
| Revenue growth (YoY) | +0.3% | ◎+13.7% | 13.4pt |
| Operating profit growth (YoY) | — | +272.6% | |
| Revenue CAGRlast 4 years | ◎+9.0% | −2.6% | 11.5pt |
| Guidance: revenue growthnext FY plan | +4.7% | ◎+19.1% | 14.5pt |
| Guidance: op. profit growthnext FY plan | — | −16.2% |
| Metric | Kyowa Kirin | Sumitomo Pharma | Gap |
|---|---|---|---|
| Share price, 1 year | +7.1% | ◎+13.9% | 6.8pt |
| Share price, 3 months | −7.0% | ◎+46.0% | 53.0pt |
| P/E (trailing)lower = cheaper | 19.2x | — | |
| Equity ratio | 80.6% | — | |
| Share price (close) | ¥2,464 | ¥1,884.5 |
◎ marks the best value for each metric. Revenue and profit are from the latest full-year earnings release; share prices are closing-price references; P/E = latest close ÷ trailing EPS. For banks and some other financials, revenue means ordinary income.
| Metric | Kyowa Kirin | Sumitomo Pharma | Gap |
|---|---|---|---|
| Average salary | ◎¥9.94M | ¥9.06M | ¥0.88M |
| Starting salary (monthly) | ◎¥265,000 | ¥245,000 | ¥20,000 |
| Average tenure | 16.5 yrs | ◎18.9 yrs | 2.4 |
| Average age | 43.2 | 44.5 | 1.3 |
| Employees | 4,013 | 1,747 | 2.3x |
Average salary is for the reporting (parent) company and is affected by average age and job mix. Holding companies with few employees are left out of the salary comparison.
Close (Oct 30, 2026)
¥2,464+7.1% (1Y)
Kyowa Kirin +7.1% over 1Y. Compared: Sumitomo Pharma +13.9%.
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Each line shows the % change from the start of the period. Updated Oct 30, 2026.
AAverage annual salary from the securities filings: Kyowa Kirin ¥9.94M, Sumitomo Pharma ¥9.06M. Kyowa Kirin pays the most. Averages also depend on staff age and job mix, so check the average age too (Kyowa Kirin 43.2, Sumitomo Pharma 44.5).
ARevenue in the latest results: Kyowa Kirin ¥496.8B, Sumitomo Pharma ¥453.3B. Kyowa Kirin (¥496.8B) and Sumitomo Pharma (¥453.3B) are about the same size by revenue.
AShare price change over the past year (closing prices, for reference): Sumitomo Pharma +13.9%, Kyowa Kirin +7.1%. Sumitomo Pharma has risen the most.
Comparing 2 companies (up to 4)
Sources: earnings releases (kessan tanshin), annual securities reports and other public information. Share prices are closing-price references, not real-time. Our data may contain errors; investment decisions are your own responsibility.
